Free Trial

LENZ Therapeutics Q1 2024 Earnings Report

LENZ Therapeutics logo
$23.49 -1.45 (-5.81%)
As of 02/21/2025 04:00 PM Eastern

LENZ Therapeutics EPS Results

Actual EPS
-$3.53
Consensus EPS
-$0.84
Beat/Miss
Missed by -$2.69
One Year Ago EPS
N/A

LENZ Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

LENZ Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

LENZ Therapeutics Earnings Headlines

LENZ Therapeutics Insiders Placed Bullish Bets Worth US$551.1k
Shocking Elon Move: Bigger than DOGE?
After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recent DOGE moves… What Elon Musk is about to do next could not only shock the world… But also put an extra $30,000 a year in your pocket.
LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics: Time For A Pause
See More LENZ Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LENZ Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENZ Therapeutics and other key companies, straight to your email.

About LENZ Therapeutics

LENZ Therapeutics (NASDAQ:LENZ), a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

View LENZ Therapeutics Profile

More Earnings Resources from MarketBeat